Search Result

Results for "

factor XIa inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Complement System (1) Factor Xa (11) Factor XI (4) Isotope-Labeled Compounds (1) Kallikrein (1) Ser/Thr Protease (1) TGF-beta/Smad (1)
By Research Areas:	Cardiovascular Disease (13) Infection (1) Inflammation/Immunology (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137431

Asundexian 5 Publications Verification BAY-2433334	Factor Xa	Cardiovascular Disease
Asundexian (BAY 2433334) is an orally active *coagulation factor* Xia (FXIa)** inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

HY-125856

Milvexian 2 Publications Verification BMS-986177; JNJ-70033093	Factor Xa	Cardiovascular Disease
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the K_i of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .

HY-128570

FD-IN-1	Complement System	Inflammation/Immunology
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC₅₀ of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC₅₀s of 7.7 and 6.5 µM, respectively .

HY-118969

BMS-262084	Factor Xa Ser/Thr Protease	Cardiovascular Disease
BMS-262084 is a potent, selective and irreversible inhibitor of **factor XIa, with an IC₅₀** of 2.8 nM against human factor XIa. BMS-262084 also inhibits human tryptase (IC₅₀=5 nM). BMS-262084 exhibits antithrombotic effects .

HY-156613

Frunexian EP-7041	Factor XI	Infection
Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a factor XIa (FXIa) inhibitor with a K_i of 0.7 nM against human FXIa and a K_i of 3 nM against rabbit FXIa. BMS-962212 blocks thrombosis while preserving normal hemostatic function. BMS-962212 is applicable to thrombosis-related research .

HY-P5542

Vicatertide SB-01; Peniel 2000	Factor Xa TGF-beta/Smad	Inflammation/Immunology
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .

HY-145354

FXIa-IN-7	Factor Xa	Cardiovascular Disease
FXIa-IN-7 is a selective and orally bioavailable **factor XIa** inhibitor with an IC₅₀ value of 0.4 nM.

HY-150519

FXIa/Plasma kallikrein-IN-1	Factor XI Kallikrein	Cardiovascular Disease
FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with K_i values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases .

HY-172400

FXIa-IN-16	Factor XI	Cardiovascular Disease
FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC₅₀ of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .

HY-125856A

Milvexian TFA BMS-986177 TFA; JNJ-70033093 TFA	Factor Xa	Cardiovascular Disease
Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .

HY-128889

FXIa-IN-1	Factor Xa	Cardiovascular Disease
FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent *heparin-derived factor* XIa (fXIa)** inhibitor .

HY-12631

BMS-654457	Factor Xa	Cardiovascular Disease
BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with K_is of 0.2 and 0.42 nM, respectively.

HY-168712

FXIa-IN-15	Factor Xa	Cardiovascular Disease
FXIa-IN-15 (Compound (S)-10h) is an inhibitor for **Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC₅₀** of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC_1.5X of 0.55 μM .

HY-137431S

Asundexian-d3 BAY-2433334-d₃	Isotope-Labeled Compounds Factor Xa	Cardiovascular Disease
Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

HY-117290A

BMS-962212 hydrochloride	Factor XI	Cardiovascular Disease
BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis .

Cat. No.	Product Name	Target	Research Area

HY-P5542

Vicatertide SB-01; Peniel 2000	Factor Xa TGF-beta/Smad	Inflammation/Immunology
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .

Cat. No.	Product Name	Chemical Structure

HY-137431S

Asundexian-d3
Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.